Rabeprazole Sodium belongs to a class of Anti-Secretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, used to prevent production of acid in the stomach, it reduces symptoms and prevents injury to the oesophagus or stomach in patients with gastroesophageal reflux disease (GERD). It has a daily dose of 10 mg minimum and 20 mg maximum. In this formulation Rabeprazole Sodium is used as an active pharmaceutical ingredient (API), and excipients such as Sodium Alginate, Guar Gum, Sodium Bicarbonate, Calcium Carbonate, Methyl Paraben, Propyl Paraben are used. In this study FTIR was done for evaluation of pure drug and to evaluate between the API and excipients, all the results were within its standard ranges. Many tests such as In-Vitro gelation time/Floating lag time, Floating time, Raft weight, Raft volume, Content uniformity, Viscosity of suspension and raft, Micromeritic study and In-Vitro drug release study was conducted and all the obtained results were within the standard ranges. Formulation SA3 and GG5 due to their linear drug release they were selected for Stability Study. 2 Months Stability Study were conducted and on each 1-Month interval readings were taken, no major difference in formulation and readings were observed after 3rd month study But, Further Long-Term stability study and In-Vivo study was recommended. Keywords: Rabeprazole Sodium, Oesophagitis, Gerd, Gastroesophageal Reflux Disorder, Raft-Forming Suspension.